Back to mobile site

Baird Reiterates Underperform Rating on Amgen (AMGN), '3Q25 Financials Look Mostly Solid'

November 5, 2025 6:08 AM EST Send to a Friend
Baird analyst Brian Skorney reiterated an Underperform rating and $215.00 price target on Amgen (NASDAQ: AMGN)The analyst comments "No change ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login